Concepedia

FAP: The Next Billion Dollar Nuclear Theranostics Target?

Jérémie Calais

Journal of Nuclear Medicine · 2020 · 118 citations · 19 references

DOIFull text

Open access

Concepts

Abstract

The recent successful clinical translation of nuclear theranostics ([1][1],[2][2]) fueled industry investment in the radiopharmaceutical market ([3][3]). Among other examples, Novartis invested $6 billion to acquire Endocyte (177Lu-PSMA-617) and Advanced Accelerator Applications (AAA; 177Lu-DOTATATE

References

19

Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors

Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text

, , +17

Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma

Paolo P. Provenzano, Carlos Cuevas, Amy Chang et al. · Cancer Cell · 2012 · 2.1K citations · Full text

, , +14

<sup>68</sup>Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer

Clemens Kratochwil, Paul Flechsig, Thomas Lindner et al. · Journal of Nuclear Medicine · 2019 · 1.4K citations · Full text

, , +17

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study

Michael S. Hofman, John Violet, Rodney J. Hicks et al. · The Lancet Oncology · 2018 · 1.1K citations

, , +14

Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein

Thomas Lindner, Anastasia Loktev, Annette Altmann et al. · Journal of Nuclear Medicine · 2018 · 920 citations · Full text

, , +17